Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has been assigned a consensus recommendation of “Hold” from the nine ratings firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $56.40.
SUPN has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th. BidaskClub lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, June 24th. Cantor Fitzgerald set a $60.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Finally, Mizuho reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, May 17th.
A number of hedge funds have recently modified their holdings of SUPN. Financial Gravity Wealth Inc. bought a new position in Supernus Pharmaceuticals in the 1st quarter worth about $44,000. Advisor Group Inc. grew its stake in Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 306 shares in the last quarter. Bremer Bank National Association bought a new position in Supernus Pharmaceuticals in the 1st quarter worth about $94,000. Huntington National Bank boosted its stake in shares of Supernus Pharmaceuticals by 881.4% during the first quarter. Huntington National Bank now owns 4,485 shares of the specialty pharmaceutical company’s stock valued at $157,000 after purchasing an additional 4,028 shares in the last quarter. Finally, Adams Diversified Equity Fund Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $200,000. Institutional investors and hedge funds own 99.29% of the company’s stock.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.44 by ($0.10). Supernus Pharmaceuticals had a return on equity of 23.60% and a net margin of 25.49%. The firm had revenue of $85.50 million during the quarter, compared to analysts’ expectations of $102.26 million. During the same period last year, the company earned $0.49 earnings per share. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. On average, equities analysts expect that Supernus Pharmaceuticals will post 2.25 EPS for the current fiscal year.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Further Reading: How Do Mutual Funds Work?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.